The HOPPEN Group announces that Après-demain SA has joined its investors Extens and Geneo in acquiring a stake in the company.
Rennes, June 22, 2023.
Groupe HOPPEN announces that Après-demain SA has become a shareholder alongside its investors Extens and Geneo.
After 4 years marked by accelerated organic and external growth, HOPPEN has established itself as the French leader in phygital support for patients and healthcare establishments, reducing the workload of caregivers.
A benchmark player in its market and recently nominated for the French Tech 2030 award, the company is taking a new step forward with the acquisition of a stake in Après-demain SA, the parent company of Debiopharm™, a life sciences company, to accelerate its growth plan in Europe and consolidate its market leadership in digital solutions for patients before, during and after hospitalization.
This announcement testifies to the attractiveness of the Group, at a time when the company is looking to accelerate its strategic development at every stage of the patient journey.
In perfect alignment with its strategy, Après-demain SA, with its in-depth knowledge of the healthcare sector healthcare sector, joins forces with existing investors Extens and Geneo. It also validates the relevance of its positioning within a fast-changing sector HOPPEN will continue to develop its expertise in patient care and continuous and continuous improvement (thanks to digital solutions combined with on-site and post-hospitalization follow-up, while drastically reducing the time and effort drastically reduce the workload for nursing staff, by giving them up to giving them up to 30% more time for their core business: care.
Already present in several European countries (Belgium, Switzerland), as well as in the Middle East, the Group intends to actively pursue its development in Europe and to conquer conquer new markets, to become the European leader in supporting in each of these countries.
Matthieu Mallédant, Chairman and CEO and co-founder of the HOPPEN Group:
Following a period of strong growth in France and the launch of a comprehensive offer for the digitalization of patient care, we are strengthening the HOPPEN group with the arrival of a European investor, who has been with us since 2019.
The progress made by our historical investors has enabled us to position the We owe them a great deal, and we're going to strengthen this pioneering and all-important position.
Today, we are continuing to roll out our strategy by launching new services for healthcare establishments in France, accelerating the roll-out of our "Ageing well" offerings, and resolutely going on the offensive in several European countries, starting with Germany, where we have just signed our first commercial partnership.
Over the past few years, we have been able to demonstrate sustained innovation efforts, which have resulted in the development of additional technological solutions and innovative services to combat a hospital crisis that is worsening and persisting. HOPPEN intends to continue along this path, to improve patient hospitalization and significantly reduce the burden on caregivers.
4 years marked by a strong acceleration in growth, the rapid expansion of its offering and the strengthening of its commitment to patients and caregivers in society
Key growth figures (2018 to 2023) :
- Sales: from €4 million to over €60 million
- Number of customers: from 45 to over 600 establishments
- Number of employees: from 38 to 630
- Number of patients cared for: from 350,000 to over 5 million patients
- Time freed up for caregivers: 30% time saved per day
Highlights 2022-2023
- Acquisition of Aklia and Exolis, strengthening the Group's leadership position and broadening the range of services it offers patients at every stage of their hospitalization;
- 1patient portal referenced on MonEspaceSanté, under the name MyGHTLimousin, citizen's digital space, under the aegis of Assurance Maladie and the French Ministry of Health of Health;
- Winner of French Tech 2030, the new support program of the France 2030 plan, operated by La French Tech alongside the Secrétariat général pour l'investissement and Bpifrance;
- Co-founder and Ambassador of French Care;
- Launch of new in-room solutions for Ageing Well in EHPAD and Senior and for people with disabilities;
- Launch of its 360° phygital support offering for healthcare establishments in the pre-admission, reception and orientation of patients;
- Partnerships with 4 players in the medical pathway (remote monitoring in oncology, etc.);
- A first commercial partnership in Germany.
Thierry Mauvernay, Chairman and CEO of Après-demain SA :
We are delighted to join forces with the Hoppen team, its historic shareholders
Extens and Geneo, and to contribute to meeting the challenge of improving quality of life for patients and caregivers, by providing them with digital quality of life for patients and caregivers, by providing them with innovative and solutions.
Valentine Deramecourt, Partner Extens:
The Hoppen Group, the French leader in digital transformation for healthcare establishments, is destined to become a key international player. Its development is a perfect illustration of Extens' investment thesis and commitment to making an impact for caregivers and patients. We are delighted to be acquiring a stake in Après-Demain, with whom we share a common vision and values.
Delphine Jarnier, Associate Director of GENEO:
This transaction marks a new stage in Hoppen's European development plan. The arrival of Après-demain SA and the commitment of all Hoppen's teams will accelerate the implementation of the Group's growth strategy.
* * *
About the company Après-demain SA
Après-demain SA is the parent company of a private Swiss family-owned group comprising a cluster of companies companies active in the life sciences sector (Debiopharm™) and a wealth diversification cluster diversified wealth management activities: Finance (cash management and equity/bond equity/bond management), Real Estate (residential and commercial), Private Equity and Investments.In particular, the Private Equity and Participations team manages a diversified portfolio of funds and direct minority holdings. Our entrepreneurial culture and our ability to and our ability to provide long-term support for the teams we invest alongside are the cornerstones of our day-to-day commitment
About Extens
Extens is France's leading healthcare software and data investment fund.
Extens invests as a reference shareholder, mainly in France and Western Europe, by Western Europe, injecting up to 15 million euros into profitable SMEs with sales 3 million, that are profitable or close to profitability. The team is made up of 13 professionals with backgrounds in private equity and the healthcare industry. Thanks to its in-depth Extens aims to turn today's players into tomorrow's champions. players into tomorrow's champions of change, by enhancing their value-creation potential in the interests of companies, their teams, shareholders and the healthcare system. healthcare system. To date, Extens has invested in 22 companies, including Enovacom, an interoperability software Kayentis, patient data collection and analysis software for clinical trials clinical trials; Teranga, publisher of a business platform for the medico-social sector; Sofia Développement, publisher of management solutions for independent paramedical professions and healthcare centers.
About GENEO Capital Entrepreneur
GENEO Capital Entrepreneur's raison d'être is to make positive finance available to the real economy.
Designed to unlock the value-creation, job-creation and impact-creation potential of SMEs and ETIs, GENEO Capital Entrepreneur has nearly 600 million euros at its disposal. In particular, it manages the "evergreen" investment company GENEO Capital, which has a 99-year lifespan and is majority-owned by families and entrepreneurs.
GENEO provides tailor-made capital that adapts to the pace of each company, ensuring responsiveness and flexibility. Its resources increase regularly as GENEO and the companies it invests grow.
As a business partner, GENEO mobilizes its teams and specialized business partners (external growth, positive impact, digital and innovation) to support the execution of structuring, growth and transformation projects. It also boasts a platform of over 70 independent experts and a Community of nearly 200 families and entrepreneurs, providing a unique opportunity to share experience and build a business network unmatched in France. The terms of this operational support are tailored to the specific needs of each company and formalized jointly by the GENEO team, the management team and the company's other shareholders in a "Carnet de croissance".
Passionate about those who make, create and want to move the lines, the GENEO team's sole ambition is to take each entrepreneur's ambition to the highest level.
At GENEOwhen we invest, we invest!
For more information: www.geneocapitalentrepreneur.com
https://twitter.com/GeneoCapital
https://www.linkedin.com/company/geneo-capital-entrepreneur
https://www.youtube.com/channel/UChZh_aqfqG-v9ANGWlLY2Tw
About the HOPPEN Group
Founded in 2011 in Rennes by Matthieu Mallédant and Sébastien Duré, and backed by financial investors - in particular EXTENS and GENEO Capital Entrepreneur since 2019 - the HOPPEN Group is the French leader in digital transformation for healthcare establishments
and healthcare establishments. The company develops technological solutions and offers a range of phygital services for patients, providing a concrete response to the major challenges facing the French healthcare system. With its unrivalled experience in the market, HOPPEN is committed on a daily basis to offering better service and a better care pathway for patients, drawing on strong values, the commitment of its 630 hospital-based employees and unrivalled technological expertise to build a healthier world. HOPPEN's solutions, used by more than 5 million patients (i.e. 1 in 2 patients in France), improve patient care and significantly enhance the daily lives of caregivers, while increasing the attractiveness and efficiency of hospitals.
https://www.hoppen.care/
List of speakers :
Après-demain SA: Sébastien Beth, Benoit Junique, Julien Leclerc, Dorothée François
Extens : Valentine Deramecourt, Arnaud Houette, Federico Miotto
GENEO Capital Entrepreneur: Delphine Jarnier, Louis Charrier
Corporate and investor legal counsel: Chammas & Marcheteau (Nicolas Lecocq, Pierre Rougemond), AVOXA (Lauriane Bobille, Beverly Guimaron)
Après-demain SA legal counsel: Latournerie Wolfrom Avocats (Christian Wolfrom, François Cado)
Financial advisor Après-demain SA: Grant Thornton (Thierry Dartus, Zakariyae El Qotni)
Vendor audit: Eight Advisory (Christophe Delas, Sandrine Vouillon)
Investment banking: Edmond de Rothschild Corporate Finance (Jean-Charles Bernard, Guillaume Jaureguiberry, Sébastien Brasy, Laurent Neubauer)
Press contact:
Séverine ARNAUD - medias@hoppen.care +332 30 31 01 40
Photos available on request